Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -9.18 USD | -30.21% |
| 2022 | -7.05 USD | 15.67% |
| 2021 | -8.36 USD | 70.22% |
| 2020 | -28.07 USD | -27.01% |
| 2019 | -22.10 USD | 51.56% |
| 2018 | -45.62 USD | 44.36% |
| 2017 | -81.99 USD | 13.1% |
| 2016 | -94.35 USD | 50.78% |
| 2015 | -191.70 USD | -99.52% |
| 2014 | -96.08 USD | 71.32% |
| 2013 | -335.02 USD | 24.35% |
| 2012 | -442.86 USD | 45.04% |
| 2011 | -805.84 USD | 5.17% |
| 2010 | -849.77 USD | 16.77% |
| 2009 | -1020.97 USD | 50.46% |
| 2008 | -2060.83 USD | -86.41% |
| 2007 | -1105.55 USD | 37.15% |
| 2006 | -1758.97 USD | 32.05% |
| 2005 | -2588.68 USD | 1.76% |
| 2004 | -2635.18 USD | -74.53% |
| 2003 | -1509.89 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.51 USD | 27.14% |
| 2024 Q1 | -0.70 USD | 83.09% |
| 2023 Q3 | -0.85 USD | 43.71% |
| 2023 Q1 | -1.38 USD | -1050.0% |
| 2023 Q2 | -1.51 USD | -9.42% |
| 2023 Q4 | -4.14 USD | -387.06% |
| 2023 FY | - USD | -30.21% |
| 2022 FY | - USD | 15.67% |
| 2022 Q3 | -1.99 USD | 4.33% |
| 2022 Q4 | -0.12 USD | 93.97% |
| 2022 Q1 | -3.10 USD | -1033233.33% |
| 2022 Q2 | -2.08 USD | 32.9% |
| 2021 Q3 | -2.26 USD | -14.14% |
| 2021 Q4 | -0.00 USD | 99.99% |
| 2021 Q1 | -3.04 USD | -253233.33% |
| 2021 Q2 | -1.98 USD | 34.87% |
| 2021 FY | - USD | 70.22% |
| 2020 FY | - USD | -27.01% |
| 2020 Q2 | -14.17 USD | -109.93% |
| 2020 Q1 | -6.75 USD | -519130.77% |
| 2020 Q4 | -0.00 USD | 99.97% |
| 2020 Q3 | -4.52 USD | 68.1% |
| 2019 Q4 | -0.00 USD | 99.97% |
| 2019 FY | - USD | 51.56% |
| 2019 Q3 | -4.99 USD | 20.16% |
| 2019 Q1 | -6.53 USD | -435233.33% |
| 2019 Q2 | -6.25 USD | 4.29% |
| 2018 FY | - USD | 44.36% |
| 2018 Q2 | -22.70 USD | 10.91% |
| 2018 Q4 | -0.00 USD | 99.99% |
| 2018 Q3 | -13.86 USD | 38.94% |
| 2018 Q1 | -25.48 USD | -519900.0% |
| 2017 Q2 | -14.86 USD | 38.54% |
| 2017 Q1 | -24.18 USD | -265614.29% |
| 2017 Q4 | -0.00 USD | 99.98% |
| 2017 Q3 | -25.17 USD | -69.38% |
| 2017 FY | - USD | 13.1% |
| 2016 Q4 | -0.01 USD | 99.96% |
| 2016 FY | - USD | 50.78% |
| 2016 Q3 | -23.98 USD | -412.39% |
| 2016 Q2 | -4.68 USD | 84.89% |
| 2016 Q1 | -30.98 USD | -333018.28% |
| 2015 Q3 | -30.68 USD | 70.64% |
| 2015 FY | - USD | -99.52% |
| 2015 Q4 | -0.01 USD | 99.97% |
| 2015 Q2 | -104.49 USD | -387.82% |
| 2015 Q1 | -21.42 USD | -382400.0% |
| 2014 Q3 | -17.07 USD | 45.74% |
| 2014 FY | - USD | 71.32% |
| 2014 Q1 | -27.27 USD | -191942.25% |
| 2014 Q2 | -31.46 USD | -15.36% |
| 2014 Q4 | -0.01 USD | 99.97% |
| 2013 FY | - USD | 24.35% |
| 2013 Q3 | -203.35 USD | -349.39% |
| 2013 Q1 | -34.75 USD | -287090.08% |
| 2013 Q4 | -0.01 USD | 99.99% |
| 2013 Q2 | -45.25 USD | -30.22% |
| 2012 Q4 | -0.01 USD | 99.98% |
| 2012 Q1 | -150.44 USD | -300179.44% |
| 2012 FY | - USD | 45.04% |
| 2012 Q2 | -310.68 USD | -106.51% |
| 2012 Q3 | -64.45 USD | 79.26% |
| 2011 Q1 | -165.06 USD | -258209.86% |
| 2011 Q4 | -0.05 USD | 99.97% |
| 2011 Q2 | -250.58 USD | -51.81% |
| 2011 FY | - USD | 5.17% |
| 2011 Q3 | -190.82 USD | 23.85% |
| 2010 Q2 | -223.06 USD | -14.68% |
| 2010 FY | - USD | 16.77% |
| 2010 Q4 | -0.06 USD | 99.97% |
| 2010 Q1 | -194.50 USD | -510398.69% |
| 2010 Q3 | -201.46 USD | 9.68% |
| 2009 Q4 | -0.04 USD | 99.98% |
| 2009 FY | - USD | 50.46% |
| 2009 Q1 | -677.74 USD | -241950.0% |
| 2009 Q2 | -268.14 USD | 60.44% |
| 2009 Q3 | -190.69 USD | 28.88% |
| 2008 Q3 | -356.44 USD | 8.64% |
| 2008 Q1 | -318.44 USD | -415076.01% |
| 2008 FY | - USD | -86.41% |
| 2008 Q4 | -0.28 USD | 99.92% |
| 2008 Q2 | -390.14 USD | -22.52% |
| 2007 Q2 | -306.12 USD | -9.01% |
| 2007 Q1 | -280.83 USD | -280730.0% |
| 2007 Q4 | -0.08 USD | 99.97% |
| 2007 Q3 | -225.20 USD | 26.43% |
| 2007 FY | - USD | 37.15% |
| 2006 Q2 | -485.80 USD | 12.3% |
| 2006 Q4 | -0.10 USD | 99.97% |
| 2006 Q3 | -321.36 USD | 33.85% |
| 2006 FY | - USD | 32.05% |
| 2006 Q1 | -553.94 USD | -395571.43% |
| 2005 Q3 | -593.34 USD | 16.37% |
| 2005 Q1 | -712.28 USD | -245513.79% |
| 2005 FY | - USD | 1.76% |
| 2005 Q2 | -709.50 USD | 0.39% |
| 2005 Q4 | -0.14 USD | 99.98% |
| 2004 Q2 | -559.65 USD | -16.32% |
| 2004 Q1 | -481.15 USD | -300618.75% |
| 2004 Q3 | -514.48 USD | 8.07% |
| 2004 Q4 | -0.29 USD | 99.94% |
| 2004 FY | - USD | -74.53% |
| 2003 Q2 | -440.40 USD | -106.83% |
| 2003 Q4 | -563.77 USD | 99.96% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | -395.14 USD | 10.28% |
| 2003 Q1 | -212.93 USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -1430.0% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | 13.964% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | -380.628% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | -401.639% |
| Azitra, Inc. | -54.76 USD | 83.236% |
| Can-Fite BioPharma Ltd. | -1.79 USD | -412.849% |
| Chromocell Therapeutics Corporation | -1.28 USD | -617.188% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | -430.636% |
| CEL-SCI Corporation | -0.73 USD | -1157.534% |
| iBio, Inc. | -6.50 USD | -41.231% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -7550.0% |
| MAIA Biotechnology, Inc. | -1.49 USD | -516.107% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | -73.864% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -1455.932% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 93.379% |
| NanoViricides, Inc. | -0.70 USD | -1211.429% |
| BiomX Inc. | -5.10 USD | -80.0% |
| BiomX Inc. | -5.10 USD | -80.0% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 7750.0% |
| Palatin Technologies, Inc. | -2.02 USD | -354.455% |
| Scorpius Holdings, Inc. | -347.20 USD | 97.356% |